Xencor, Inc. $XNCR Shares Acquired by Aberdeen Group plc

Key Points

• Aberdeen Group plc increased its holdings in Xencor, Inc. by 114.9%, owning 377,112 shares valued at $4,012,000 as of the last quarter.
• Xencor reported a quarterly earnings per share of ($0.41), exceeding analysts' expectations of ($0.78) and showing significant revenue growth of 82.4% year-over-year.
• Analyst ratings for Xencor are mixed, with seven analysts rating it a Buy and Barclays setting a notably low target price of $6.00, while the average target remains around $26.43.

Aberdeen Group plc boosted its position in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 114.9% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 377,112 shares of the biopharmaceutical company's stock after purchasing an additional 201,592 shares during the quarter. Aberdeen Group plc owned approximately 0.53% of Xencor worth $4,012,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in XNCR. LPL Financial LLC raised its holdings in Xencor by 12.0% in the fourth quarter. LPL Financial LLC now owns 19,680 shares of the biopharmaceutical company's stock worth $452,000 after purchasing an additional 2,113 shares in the last quarter. Wells Fargo & Company MN raised its holdings in Xencor by 50.7% in the fourth quarter. Wells Fargo & Company MN now owns 36,086 shares of the biopharmaceutical company's stock worth $829,000 after purchasing an additional 12,144 shares in the last quarter. Bank of Montreal Can bought a new position in Xencor in the fourth quarter worth about $239,000. Raymond James Financial Inc. acquired a new position in shares of Xencor during the fourth quarter valued at about $2,329,000. Finally, Sterling Capital Management LLC increased its holdings in shares of Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 1,040 shares in the last quarter.

Xencor Trading Down 1.4%

Xencor stock traded down $0.11 during mid-day trading on Tuesday, hitting $7.90. The company had a trading volume of 778,770 shares, compared to its average volume of 730,903. Xencor, Inc. has a 12-month low of $6.92 and a 12-month high of $27.24. The company's fifty day moving average is $8.31 and its 200-day moving average is $10.04. The company has a market capitalization of $563.43 million, a price-to-earnings ratio of -3.29 and a beta of 0.89.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.37. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.The business had revenue of $43.61 million for the quarter, compared to analyst estimates of $22.59 million. During the same quarter in the prior year, the firm posted ($1.07) EPS. The business's quarterly revenue was up 82.4% compared to the same quarter last year. As a group, sell-side analysts expect that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on XNCR. Royal Bank Of Canada cut their price objective on shares of Xencor from $32.00 to $15.00 and set an "outperform" rating on the stock in a report on Thursday, August 21st. Wedbush cut their price objective on shares of Xencor from $31.00 to $26.00 and set an "outperform" rating on the stock in a report on Thursday, August 7th. Barclays cut their price objective on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a report on Thursday, May 8th. Finally, Wells Fargo & Company cut their price objective on shares of Xencor from $33.00 to $27.00 and set an "overweight" rating on the stock in a report on Thursday, August 7th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.71.

Insiders Place Their Bets

In other Xencor news, Director Ellen Feigal sold 2,993 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the sale, the director owned 19,183 shares in the company, valued at approximately $176,867.26. This represents a 13.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Richard J. Ranieri sold 2,993 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the transaction, the director directly owned 19,183 shares of the company's stock, valued at approximately $176,867.26. The trade was a 13.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,194 shares of company stock worth $103,209. Corporate insiders own 5.23% of the company's stock.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.